Skip to content
Peptidepedia

TB-500 Research: Clinical Studies, Evidence & Scientific Review (2026)

From Peptidepedia, the trusted peptide wiki.

Research Evidence

Thymosin beta-4 and its derivatives have been studied in various preclinical and clinical contexts. Phase II clinical trials have evaluated TB4 for dermal wound healing, with results demonstrating accelerated repair in patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds. These trials concluded that TB4 is safe, well-tolerated, and shows promise for skin regeneration applications.

Cardiac Research: Studies in animal models demonstrated that TB4 administration following coronary artery ligation enhanced myocyte survival and improved cardiac function. Research in porcine models of ischemic heart disease has further supported the therapeutic potential of thymosin beta-4 for cardiac applications.

Neurological Research: Neurological research has explored TB4's neuroprotective and neurorestorative effects, with studies suggesting potential applications for traumatic brain injury treatment.

Key Limitation: Most human-relevant research has focused on the parent compound thymosin beta-4 rather than the TB-500 fragment specifically, and large-scale clinical trials for musculoskeletal applications in humans remain limited.

Frequently Asked Questions

Clinical trials of thymosin beta-4 have demonstrated that it is safe and well-tolerated at therapeutic doses in animals. However, long-term safety data specifically for TB-500 in humans is limited, and potential risks from unregulated products include contamination and inconsistent dosing.

While some users prefer injecting near injury sites, TB-500's low molecular weight allows it to travel systemically throughout the body. Research suggests beneficial effects occur regardless of whether the peptide is administered locally or at a distant site.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Goldstein AL, Kleinman HK. Minireview: Crosstalk between thymosin β4 and the chemokine network. Ann N Y Acad Sci. 2015.
  2. Philp D, Kleinman HK. Animal studies with thymosin β4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2012.
  3. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999.
  4. Smart N, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007.
  5. RegeneRx Biopharmaceuticals. Phase II Clinical Trials: Thymosin Beta-4 for Dermal Wound Healing.
  6. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  7. Drip Hydration. The Wolverine Stack: Can BPC 157 and TB 500 Accelerate Injury Recovery?
  8. Examine.com. Thymosin Beta-4 Research Breakdown.
  9. U.S. Food and Drug Administration. Bulk Drug Substances Under Evaluation for Use in Compounding Under Section 503A.
←Read the full TB-500 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”